Charles River Laboratories International (CRL) EBIT (2009 - 2025)

Charles River Laboratories International's EBIT history runs 17 years deep, the most recent figure standing at -$283.4 million for Q4 2025.

• In Q4 2025, EBIT fell 69.03% year-over-year to -$283.4 million; the TTM figure through Dec 2025 stood at $25.2 million (down 88.93% YoY), while the FY2025 annual figure was $25.2 million, down 88.93% from the prior year.
• EBIT for Q4 2025 stood at -$283.4 million, down from $133.8 million in the prior quarter.
• The five-year high for EBIT was $187.4 million in Q2 2022, with the low at -$283.4 million in Q4 2025.
• The 5-year median for EBIT is $143.2 million (2021), against an average of $105.5 million.
• The sharpest annual moves came in 2021 and 2024: EBIT surged 79.18% in 2021, then slumped 226.15% in 2024.
• Charles River Laboratories International's EBIT stood at $172.8 million in 2021, then decreased by 5.21% to $163.8 million in 2022, then fell by 18.86% to $132.9 million in 2023, then plunged by 226.15% to -$167.7 million in 2024, then slumped by 69.03% to -$283.4 million in 2025.
• Business Quant data shows CRL's EBIT at -$283.4 million in Q4 2025, $133.8 million in Q3 2025, and $100.1 million in Q2 2025.